Saneca Pharma strengthens senior team
Jeremy Drummond will focus on growing the CDMO’s API and finished dosage form development and manufacturing business in Europe and North America.
Slovakia-based CDMO, Saneca Pharma, has added senior talent to its team to position the company for its next phase of growth.
With a background in the pharmaceutical contract services industry spanning over 20 years, Jeremy Drummond joins the CDMO as sales and marketing director.
Jeremy will be focused on growing Saneca Pharma’s API and finished dosage form development and manufacturing business in Europe and North America.
Juraj Kubáň also joins the CDMO in the role of project development manager. With a background in pharmaceutical project management and a PhD in organic chemistry, Juraj will assist Saneca Pharma’s customers with the efficient transfer of products from API through to finished dosage form.
Anthony Sheehan, CEO at Saneca Pharma said: “Our site has a strong big pharma heritage, with over 70 years’ expertise in producing APIs and finished dosage forms. Following the company’s transition to CDMO, a key focus is to ensure the market and customers understand what makes the Saneca Pharma offering different.
“Adding the likes of Jeremy and Juraj to our senior management team underlines our commitment to be the outsourcing partner of choice for pharmaceutical companies in need of a technically agile and responsive CDMO. Both have exceptional experience in the contract services sector that will help ensure we compete with the biggest CMOs and CDMOs across the globe.”
From its site in Hlohovec, Slovakia, Saneca Pharma provides full service development and manufacturing capabilities for APIs and finished dosage forms. With particular expertise in controlled substances, the CDMO can produce opiate products from ‘farm to pharmacy’, simplifying the supply chain for its customers.
Jeremy said: “As the biggest pharmaceutical company in Slovakia with significant growth plans for the contract manufacturing business, it’s an exciting time to join Saneca. We are well positioned to offer a fully integrated drug development, manufacturing and supply service thanks to the range of technologies and quality of pharmaceutical expertise found on our site.
“We expect to experience steady growth in the coming months as our team has the technical agility to handle multi-step products, complex molecules, novel release mechanisms and patient compliance challenges; services that are in demand in today’s market.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance